

April 15, 2025

The Manager- Listing
BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

This is to inform that AstraZeneca Pharma India Limited had vide its letter dated November 21, 2023, informed the receipt of Marketing Authorisation dated November 17, 2023 for Olaparib film-coated tablets 100mg and 150mg (Lynparza) which was indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer.

Through this letter, we wish to inform that the Company has now surrendered the marketing authorisation of the above-mentioned indication of Olaparib (Lynparza) 100mg and 150mg.

We also confirm that since the date of receipt of Marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India.

Please be informed the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons.

Further, we would like to inform you that we continue to hold all other existing permissions for the said drug Olaparib in India.

We request you to take the above intimation on record.

Thanking you

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary